GX Sponsor LLC - 16 Jul 2021 Form 4 Insider Report for Celularity Inc (CELU)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
20 Jul 2021, 21:34:58 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jay R. Bloom, Authorized Signatory

Key filing fact

GX Sponsor LLC filed Form 4 for Celularity Inc (CELU) on 20 Jul 2021.

Key facts

  • This page summarizes GX Sponsor LLC's Form 4 filing for Celularity Inc (CELU).
  • 5 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 20 Jul 2021, 21:34.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: +$7,000,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CELU transaction

Class A Common Stock

Conversion of derivative security

Transaction value
$0
Shares
+7,187,500
Change %
Price
$0.000000
Shares after
7,187,500
Date
16 Jul 2021
Ownership
Direct
Footnotes
F1, F2, F3
CELU transaction

Class A Common Stock

Other

Transaction value
$0
Shares
-7,087,500
Change %
-99%
Price
$0.000000
Shares after
100,000
Date
16 Jul 2021
Ownership
Direct
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CELU transaction Derivative

Class B Common Stock

Conversion of derivative security

Transaction value
$0
Shares
-7,187,500
Change %
-100%
Price
$0.000000*
Shares after
0
Date
16 Jul 2021
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
7,187,500
Exercise price
Footnotes
F1
CELU transaction Derivative

Warrants

Award

Transaction value
$7,000,000
Shares
+7,000,000
Change %
Price
$1.00
Shares after
7,000,000
Date
16 Jul 2021
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
7,000,000
Exercise price
$11.50
Footnotes
F5, F6, F7
CELU transaction Derivative

Warrants

Other

Transaction value
Shares
-7,000,000
Change %
-100%
Price
Shares after
0
Date
16 Jul 2021
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
7,000,000
Exercise price
$11.50
Footnotes
F6, F7, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

GX Sponsor LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

On July 16, 2021, in connection with the consummation of the business combination (the "Business Combination") among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc., pursuant to that certain Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021, each share of Class B common stock of GX held by GX Sponsor LLC ("Sponsor") automatically converted into one share of Class A common stock ("Common Stock") of Celularity Inc., formerly known as GX Acquisition Corp. (the "Issuer").

Footnote F2

25% of the shares are subject to vesting. Such shares shall vest on the first day that the volume weighted average price of the Common Stock on Nasdaq is at or above $12.00 for 20 trading days over a 30 consecutive trading day period immediately preceding such day. Shares that do not vest by July 15, 2031 will be forfeited. Vesting is subject to acceleration upon certain change of control events at the Issuer.

Footnote F3

Sponsor is the record holder of these securities. Cooper Road, LLC (an entity controlled by Jay R. Bloom) and Dean C. Kehler are the managing members of Sponsor, and as such Messrs. Bloom and Kehler have voting and investment discretion with respect to the securities held of record by Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by Sponsor. Each such entity or person disclaims any beneficial ownership of the reported securities other than to the extent of any pecuniary interest they may have therein, directly or indirectly.

Footnote F4

Represents a pro rata distribution of Common Stock to direct and indirect members of Sponsor.

Footnote F5

Reflects warrants of the Issuer ("Private Warrants"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. These Private Warrants were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination, which occurred on July 16, 2021.

Footnote F6

The warrants will become exercisable 30 days after the completion of the Business Combination.

Footnote F7

The warrants will expire on the fifth anniversary of the completion of the Business Combination.

Footnote F8

Represents a pro rata distribution of Private Warrants to direct and indirect members of Sponsor.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .